Faraday Pharmaceuticals has a total of 39 patents globally, out of which 7 have been granted. Of these 39 patents, more than 33% patents are active. The United States of America is where Faraday Pharmaceuticals has filed the maximum number of patents, followed by Australia and Europe. Parallely, United States of America seems to be the main focused R&D centre and also is the origin country of Faraday Pharmaceuticals.
Faraday Pharmaceuticals was founded in 2014. The Company is an early-stage biopharmaceutical firm focused on discovering innovative medicines to address ischemia-reperfusion injury. It has licensed patented liquid formulations of reduced nonmetal gaseous elements created by Dr. Mark Roth’s group at the Fred Hutchinson Cancer Research Center.
Do read about some of the most popular patents of Faraday Pharmaceuticals which have been covered by us in this article and also you can find Faraday Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Faraday Pharmaceuticals patent portfolio.
How many patents does Faraday Pharmaceuticals have?
Faraday Pharmaceuticals has a total of 39 patents globally. These patents belong to 17 unique patent families. Out of 39 patents, 13 patents are active.
How Many Patents did Faraday Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Faraday Pharmaceuticals Applications Filed | Faraday Pharmaceuticals Patents Granted |
| 2022 | 2 | – |
| 2021 | 1 | – |
| 2020 | 8 | – |
| 2019 | 6 | – |
| 2018 | 2 | – |
| 2011 | – | 1 |
How many Faraday Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did Faraday Pharmaceuticals File in Different Countries?
Countries in which Faraday Pharmaceuticals Filed Patents
| Country | Patent |
| United States Of America | 7 |
| Australia | 5 |
| Europe | 3 |
| Israel | 2 |
| Germany | 2 |
| Mexico | 2 |
| Canada | 2 |
| India | 1 |
| New Zealand | 1 |
| Ireland | 1 |
| Austria | 1 |
| Hong Kong (S.A.R.) | 1 |
Where are Research Centers of Faraday Pharmaceuticals Patents Located?
Best Faraday Pharmaceuticals Patent
US20060270741A1 is the most popular patent in the Faraday Pharmaceuticals portfolio. It has received 20 citations so far from companies like Signal Biosciences, Astellas Pharma and Lycera Corporation.
What Percentage of Faraday Pharmaceuticals US Patent Applications Were Granted?
Faraday Pharmaceuticals (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.
Below are the key stats of Faraday Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Faraday Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Cooley Llp | 2 | 0% |
List of Faraday Pharmaceuticals Patents
| Faraday Pharmaceuticals Patents | Title |
| US20220387483A1 | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| US20210252047A1 | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| CA3160144A1 | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| CA3102792A1 | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| AU2020417997A1 | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| AU2019282820A1 | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| IL292688A | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| IL279221A | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| MX2022005347A | Use Of Iodide Compounds For The Treatment And Prevention Of Cachexia And Cardiotoxicity Associated With Chemotherapy |
| IN202217030541A | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| HK40050755A | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| NZ788676A | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| MX2020013306A | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome. |
| US8038995B2 | Human N-Type Calcium Channel Isoform And Uses Thereof |
| US7651175B2 | Parking Brake System |
| US20200096496A1 | Iodide Detection In Blood Plasma Samples |
| US20070265348A1 | Therapeutic Guanidines |
| US20060270741A1 | Pharmaceutically Active Compounds And Methods Of Use |
| DE69233479T2 | Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And New Method For Identifying Inhibitors Of Neurotransmitter Release |
| DE69233479D1 | Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And New Method For Identifying Inhibitors Of Neurotransmitter Release |
| EP0940139B1 | Substituted Guanidines And Derivatives Thereof As Modulators Of Neurotransmitter Release And Novel Methodology For Identifying Neurotransmitter Release Blockers |
| EP4054593A1 | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| EP3801565A4 | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| AT288262T | Substituierte Guanidine Und Derivate Hiervon Als Modulatoren Der Freisetzung Von Neurotransmittern Und Neue Methode Zur Identifizierung Von Inhibitoren Der Neurotransmitter-Freisetzung |
| IE20030530A1 | Guanidines And Derivatives |
| WO2021137932A1 | Use Of Iodide Compounds For The Treatment And Prevention Of Chemotherapy-Associated Cachexia And Cardiotoxicity |
| WO2019237065A1 | Use Of Halogen Compounds For The Treatment And Prevention Of Tissue Injury And Post-Intensive Care Syndrome |
| WO2018232179A1 | Iodide Detection In Blood Plasma Samples |
| WO2005097112A3 | Ion Channel Modulators |
| WO2005086892A3 | Ion Channel Modulators |
| WO2005086836A3 | Ion Channel Modulators |
| WO2005001060A3 | Novel Calcium Channel |
| WO2004072255A3 | Methods Of Treating Disease |
| WO2004071433A3 | Methods Of Treating Disease |
| WO2004072615A2 | Methods For Identifying Ion Channel Modulators |
| WO2003095620A3 | Oocyte Recording Chamber |
| AU2003203801B8 | Pharmaceutically Active Compounds And Methods Of Use |
| AU771437B2 | Methods For Treating Neurological Injuries And Disorders |
| AU2003228950A1 | Oocyte Recording Chamber |
What are Faraday Pharmaceuticals key innovation segments?
What Technologies are Covered by Faraday Pharmaceuticals?
The chart below distributes patents filed by Faraday Pharmaceuticals